Strategic Partnership for Clinical R&D in China worth $4M
Filed with ASX · · 4 pages · English
Story so far
Earlier from Osteopore
- Largest South African Medical Insurer provides cover for OSX
- Activities Update Qtr Ending March 2023 and Appendix 4C
- OSX Successfully transitions to EU Medical Device Regulation
- Reinstatement of Security Class to Quotation
- Security Class Suspension from Quotation
Later from Osteopore
- Osteopore strengthens Board & Management by key appointments
- OSX receives A$10m commitment for commercialisation in China
- Activities Update Qtr Ending June 2023 and Appendix 4C
- MOU with Temasek-linked Innoventures - Orthopaedics in China
- Activities Update Qtr Ending September 2023 and Appendix 4C
Follow Osteopore into a list and get an email when it puts out news.
Follow Osteopore